Anti-vascular endothelial growth factor (VEGF) therapy is the standard of care for treating wet age-related macular degeneration (AMD), with several commercially available options. The continued strong uptake of Eylea in Europe threatens Lucentis’s historical position as the patient-share leader in this market, while use of off-label Avastin differs across the EU5 countries. Additionally, with no currently available treatments, there is commercial opportunity for first-to-market dry AMD therapies. The Age-Related Macular Degeneration Current Treatment Overview provides a synopsis of current treatment goals, key therapies, and medical practice in the G7 markets. The detailed, expanded analysis in Dry and Wet Age-Related Macular Degeneration Current Treatment EU offers a snapshot of how EU5 ophthalmologists are currently managing their dry and wet AMD patients, with a particular focus on the use of anti-VEGF for wet AMD, as well as insight into the factors driving such prescribing habits.
- Dry And Wet Age-Related Macular Degeneration - Current Treatment - Detailed Expanded Analysis (EU)
Author(s): Sarah Soucy
Sarah Soucy, M.S., is a Business Insights Analyst with the central nervous system/ophthalmology disorders group at Decision Resources Group. She has authored primary research and insights for dry and wet age-related macular degeneration and multiple sclerosis.
Prior to joining DRG, Ms. Soucy spent six years on the client side as a scientist at Pfizer in the inflammation and immunology research group with both in vitro and in vivo experience. She earned her B.S. in Animal Science with a Bioscience and Technology option and her M.S. in Nutritional Sciences from the University of New Hampshire, Durham, where she studied disordered metabolism